“Longevity equality is the whole ball game”

Ahead of the longevity show, Poonam Desai discusses gender-specific medications, preventative care and the dangers of longevity becoming a luxury.

The longevity section is very fond of the word “personal”; biomarker panels, custom supplement stacks, and artificial intelligence are now wrapped in the language of precision medicine. Despite all the complexity, many of the frameworks that underpin modern health care still derive from a model that viewed male biology as the standard and female biology as deviance—a historical construct that is increasingly difficult to defend in an era seemingly defined by individualized care.

These tensions sit at the heart of the upcoming session Longevity showwhich will be held in London this July. In a panel investigating gender differences in longevityDr Poonam Desai joins Professor Mike Kirby, Dr Helen O’Neill and Siobhan Mitchell to explore how research bias, diagnostic gaps and unequal access continue to shape health outcomes for both women and men across the lifespan. Desai — a board-certified lifestyle and precision medicine physician and founder of Longevity Place and HER Longevity — has become an increasingly prominent voice in the preventive-health space, particularly around women’s health and the clinical blind spots that continue to surround it.

Longevity.Technology: Longevity medicine has talked about personalization for years – but as this discussion on The Longevity Show makes clear, personalization is a very empty concept if the underlying system still treats male biology as a default parameter and female biology as a subject option. The reality is not as futuristic as the marketing pitch might suggest; many of the clinical frameworks that underlie modern health care are built on research that completely excludes women, while men often underperform under cultural assumptions that undermine preventive care or reduce health conversations to stoicism with better tailoring. The result is a peculiar kind of equality in dysfunction – different blind spots, different outcomes, a systemic problem. In this context, Dr. Poonam Desai’s observations land with particular force; longevity is not just about extending life through ever more sophisticated diagnosis and interventions, but also questioning who these interventions are designed for in the first place. As the field matures—and fringes from elite optimization culture to something like mainstream medicine—questions around menopause, andropause, sex-specific risk, and equitable access seem less relevant and more fundamental. After all, a health care system cannot realistically claim to promote longevity for all while large sections of the population are still being evaluated from a point of reference that was never created with them in mind.

Restoring the protocol

For Desai, the problem begins with the architecture of medicine itself. “We have historically used ‘average man’ as the default biological subject,” he says, arguing that the term itself masks a century of methodological convenience rather than scientific rigor.

“We rewrite them and recognize that the ‘average man’ was never average to begin with – he was just convenient.”

Until 1993, women were largely excluded from clinical trials in the United States, meaning that many dosing protocols, biomarker ranges, and treatment assumptions were calibrated using male physiology. Desai asserts that the implications continue through clinical practice today.

Redressing this disparity, Desai argues, requires more than symbolic coverage. “Practically, rewriting these protocols means requiring sex-specific data in every study we cite, recalibrating the reference ranges for things like ferritin, TSH, and testosterone to reflect what’s optimal for women, not just what’s statistically common, and integrating the menstrual cycle, perimenopause, and premenstrual cycle as the physiological variables that explain how we structure drugs and interventions.”

“It also means training the next generation of doctors to stop treating women as little men with complicated hormones,” she adds.

The criticism has particular resonance in longevity medicine, where prevention depends on biomarker interpretation and risk stratification; A reference range is not just an administrative detail, but a framework through which future disease is predicted or missed.

The paradox of longevity

According to statistics, women live longer than men. However, they also spend many years in poor health—a discrepancy that Desai believes is often characterized as a biological inevitability rather than the cumulative effect of delayed diagnosis and neglected research.

“It’s both and pretending is how we got here in the first place.”

She points to cardiovascular disease, which often presents differently in women and is still an underdiagnosed emergency, as well as autoimmune conditions that disproportionately affect women and take years to diagnose. Perimenopause, despite affecting every woman who lives long enough, is remarkably underrepresented in medical education.

“Yes, it’s a diagnostic failure. But it’s a biological subtlety that we overlooked because hormones aren’t a footnote to female physiology, they’re an operating system, and we treated them like quarterly software updates.”

There is a subtle but important change here. Discussions of menopause are increasingly moving beyond lifestyle and into basic longevity science—not just as a quality-of-life concern, but as a critical transition that affects cardiovascular, metabolic, muscle, and bone aging trajectories.

“Women don’t get sick more because their biology is more complex,” says Desai. “They live sicker lives because their biology is less prioritized.”

Personalization and its limits

Desai is similarly skeptical of longevity medicine’s tendency to conflate personalization with exclusivity. The science of extending health may be advancing rapidly, he says, but the systems needed to deliver these interventions equitably have lagged behind.

“Longevity medicine will either be a democratic force in health care or the most stratified, and which will be decided by us now, in rooms like this.”

For Desai, equity in longevity is not a secondary ethical consideration, but a defining structural issue for the field itself. “The science of extending the lifespan of health is moving faster than the infrastructure to deliver it equitably, and if we don’t enable access to the infrastructure, we’ll end up with a two-tiered system where the rich live healthier lives into their nineties and everyone else inherits the burden of chronic disease we already have, just with better marketing.”

This concern comes at a time when many comprehensive preventive services are concentrated within concierge clinics and premium subscription models – primarily available to affluent patients who can afford to pay for screening, ongoing monitoring and individualized optimization.

“If your longevity medicine only works for people who can afford a concierge clinic, you’re not doing longevity medicine, you’re selling a luxury.”

It’s a deliberately edgy design, though it’s gaining traction in public health and policy circles. As health care systems face the economic realities of aging, prevention is becoming less of a consumer preference and more of an infrastructure.

Another protocol

As the discussion turns to personalized medicine itself, Desai repeatedly returns to a central point; The gender-specific biology of not only how aging manifests, but also how interventions should be structured in response.

“This changes everything, because aging is not a gender-neutral process, and pretending it is has cost women decades of health.”

Women, he explains, “experience a relatively sudden hormonal decline during menopause that accelerates bone loss, cardiovascular risk, cognitive impairment, and metabolic changes that men simply don’t experience on the same schedule.”

This biological difference, she says, should change everything from screening schedules to therapeutic priorities. “This means that the interventions that matter, when we screen, what we measure, how we dose, and what treatments we prioritize, all need to be reconfigured around female physiology, not male data.”

“Personal health for women is not a pink version of the men’s protocol, it’s a different protocol.”

The consequences go beyond just menopause. Desai advocates for earlier cardiovascular screening in women, more attention to perimenopausal symptoms as an indicator of long-term risk, and a broader understanding of hormone therapy in longevity medicine.

“Personalized medicine that ignores gender is not personalized,” he says. “It’s just a smaller cage.”